Research ArticleArticle
Bone Area Provides a Responsive Outcome Measure for Bone Changes in Short-term Knee Osteoarthritis Studies
Michael A. Bowes, Rose A. Maciewicz, John C. Waterton, David J. Hunter and Philip G. Conaghan
The Journal of Rheumatology October 2016, jrheum.151118; DOI: https://doi.org/10.3899/jrheum.151118
Michael A. Bowes
From the Imorphics; Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester; Respiratory, Inflammation, Autoimmunity Innovative Medicines and Early Development (IMED), AstraZeneca, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia; Rheumatology Department, Royal North Shore Hospital, St. Leonards, Australia. M.A. Bowes, PhD, Imorphics; R.A. Maciewicz, PhD, Chief Scientist, Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca; J.C. Waterton, PhD, Professor of Translational Imaging, Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester; D.J. Hunter, PhD, Florance and Cope Chair of Rheumatology, Professor of Medicine, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, and Rheumatology Department, Royal North Shore Hospital; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit. Address correspondence to M.A. Bowes, Imorphics, Kilburn House, Manchester Science Park, Manchester, UK. E-mail: mike@imorphics.com. Accepted for publication August 11, 2016.
Rose A. Maciewicz
From the Imorphics; Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester; Respiratory, Inflammation, Autoimmunity Innovative Medicines and Early Development (IMED), AstraZeneca, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia; Rheumatology Department, Royal North Shore Hospital, St. Leonards, Australia. M.A. Bowes, PhD, Imorphics; R.A. Maciewicz, PhD, Chief Scientist, Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca; J.C. Waterton, PhD, Professor of Translational Imaging, Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester; D.J. Hunter, PhD, Florance and Cope Chair of Rheumatology, Professor of Medicine, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, and Rheumatology Department, Royal North Shore Hospital; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit. Address correspondence to M.A. Bowes, Imorphics, Kilburn House, Manchester Science Park, Manchester, UK. E-mail: mike@imorphics.com. Accepted for publication August 11, 2016.
John C. Waterton
From the Imorphics; Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester; Respiratory, Inflammation, Autoimmunity Innovative Medicines and Early Development (IMED), AstraZeneca, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia; Rheumatology Department, Royal North Shore Hospital, St. Leonards, Australia. M.A. Bowes, PhD, Imorphics; R.A. Maciewicz, PhD, Chief Scientist, Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca; J.C. Waterton, PhD, Professor of Translational Imaging, Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester; D.J. Hunter, PhD, Florance and Cope Chair of Rheumatology, Professor of Medicine, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, and Rheumatology Department, Royal North Shore Hospital; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit. Address correspondence to M.A. Bowes, Imorphics, Kilburn House, Manchester Science Park, Manchester, UK. E-mail: mike@imorphics.com. Accepted for publication August 11, 2016.
David J. Hunter
From the Imorphics; Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester; Respiratory, Inflammation, Autoimmunity Innovative Medicines and Early Development (IMED), AstraZeneca, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia; Rheumatology Department, Royal North Shore Hospital, St. Leonards, Australia. M.A. Bowes, PhD, Imorphics; R.A. Maciewicz, PhD, Chief Scientist, Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca; J.C. Waterton, PhD, Professor of Translational Imaging, Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester; D.J. Hunter, PhD, Florance and Cope Chair of Rheumatology, Professor of Medicine, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, and Rheumatology Department, Royal North Shore Hospital; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit. Address correspondence to M.A. Bowes, Imorphics, Kilburn House, Manchester Science Park, Manchester, UK. E-mail: mike@imorphics.com. Accepted for publication August 11, 2016.
Philip G. Conaghan
From the Imorphics; Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester; Respiratory, Inflammation, Autoimmunity Innovative Medicines and Early Development (IMED), AstraZeneca, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia; Rheumatology Department, Royal North Shore Hospital, St. Leonards, Australia. M.A. Bowes, PhD, Imorphics; R.A. Maciewicz, PhD, Chief Scientist, Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca; J.C. Waterton, PhD, Professor of Translational Imaging, Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester; D.J. Hunter, PhD, Florance and Cope Chair of Rheumatology, Professor of Medicine, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, and Rheumatology Department, Royal North Shore Hospital; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit. Address correspondence to M.A. Bowes, Imorphics, Kilburn House, Manchester Science Park, Manchester, UK. E-mail: mike@imorphics.com. Accepted for publication August 11, 2016.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Bone Area Provides a Responsive Outcome Measure for Bone Changes in Short-term Knee Osteoarthritis Studies
Michael A. Bowes, Rose A. Maciewicz, John C. Waterton, David J. Hunter, Philip G. Conaghan
The Journal of Rheumatology Oct 2016, jrheum.151118; DOI: 10.3899/jrheum.151118